United Therapeutics (NASDAQ:UTHR) Price Target Raised to $400.00

United Therapeutics (NASDAQ:UTHR) had its price objective boosted by equities researchers at TD Cowen from $350.00 to $400.00 in a research note issued on Monday, Benzinga reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock. TD Cowen’s price objective would suggest a potential upside of 8.03% from the stock’s previous close.

UTHR has been the topic of several other reports. StockNews.com raised United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 17th. Bank of America lowered their price target on United Therapeutics from $303.00 to $280.00 and set an “underperform” rating on the stock in a report on Thursday, August 1st. UBS Group upped their target price on shares of United Therapeutics from $300.00 to $370.00 and gave the company a “buy” rating in a report on Monday, July 8th. Morgan Stanley lowered United Therapeutics from an “overweight” rating to an “equal weight” rating and upped their price objective for the stock from $310.00 to $321.00 in a research note on Thursday, July 11th. Finally, HC Wainwright reiterated a “buy” rating and set a $400.00 target price on shares of United Therapeutics in a research report on Thursday, August 1st. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $361.33.

United Therapeutics Stock Performance

United Therapeutics stock opened at $370.26 on Monday. The company has a quick ratio of 4.18, a current ratio of 4.35 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $16.47 billion, a P/E ratio of 17.02, a PEG ratio of 1.34 and a beta of 0.57. The stock’s 50 day moving average is $351.40 and its 200 day moving average is $309.96. United Therapeutics has a twelve month low of $208.62 and a twelve month high of $377.03.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.33 by ($0.48). The business had revenue of $714.90 million during the quarter, compared to the consensus estimate of $691.87 million. United Therapeutics had a net margin of 40.87% and a return on equity of 18.82%. The business’s revenue was up 19.8% compared to the same quarter last year. During the same period last year, the company posted $5.24 earnings per share. On average, equities research analysts predict that United Therapeutics will post 24.72 earnings per share for the current fiscal year.

Insider Transactions at United Therapeutics

In other news, CFO James Edgemond sold 7,782 shares of the business’s stock in a transaction on Monday, October 21st. The shares were sold at an average price of $366.99, for a total value of $2,855,916.18. Following the transaction, the chief financial officer now owns 6,426 shares of the company’s stock, valued at approximately $2,358,277.74. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CEO Martine A. Rothblatt sold 3,600 shares of the business’s stock in a transaction on Friday, July 26th. The shares were sold at an average price of $338.61, for a total value of $1,218,996.00. Following the sale, the chief executive officer now owns 130 shares in the company, valued at approximately $44,019.30. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO James Edgemond sold 7,782 shares of the business’s stock in a transaction on Monday, October 21st. The shares were sold at an average price of $366.99, for a total transaction of $2,855,916.18. Following the transaction, the chief financial officer now owns 6,426 shares in the company, valued at $2,358,277.74. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 106,412 shares of company stock valued at $36,470,922. 11.90% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of UTHR. LSV Asset Management grew its holdings in shares of United Therapeutics by 82.5% in the second quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company’s stock worth $307,837,000 after purchasing an additional 436,851 shares during the last quarter. Swedbank AB bought a new position in shares of United Therapeutics in the first quarter worth about $97,316,000. Nordea Investment Management AB grew its holdings in shares of United Therapeutics by 677.6% in the first quarter. Nordea Investment Management AB now owns 300,920 shares of the biotechnology company’s stock worth $72,422,000 after purchasing an additional 262,222 shares during the last quarter. Canada Pension Plan Investment Board grew its holdings in shares of United Therapeutics by 567.2% in the first quarter. Canada Pension Plan Investment Board now owns 180,800 shares of the biotechnology company’s stock worth $41,533,000 after purchasing an additional 153,700 shares during the last quarter. Finally, Pacer Advisors Inc. lifted its stake in United Therapeutics by 19.6% in the second quarter. Pacer Advisors Inc. now owns 561,834 shares of the biotechnology company’s stock worth $178,972,000 after acquiring an additional 92,240 shares during the period. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.